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doi:10.1016/j.kjms.2010.11.007Abstract We evaluated the performance of a hepatitis C virus (HCV) antigen/antibody
combination test [Murex HCV Antigen/Antibody Combination Test (Murex Ag/Ab test)] by
comparing it with the current third-generation HCV antibody enzyme immunoassay (anti-
HCV). A total of 403 serum samples were consecutively collected from four patient groups:
healthy controls (nZ 100); HCV-infected patients (HCV group, nZ 102); Human immunodefi-
ciency virus (HIV)/HCV-infected patients (HIV/HCV group, nZ 100); and patients with uremia
(uremia group, nZ 101). Performances were evaluated for the Murex Ag/Ab, anti-HCV, and
HCV RNA in the HIV/HCV and uremia patient groups. In the HCV group, all 102 samples showed
concordant positive and negative results for anti-HCV, Murex Ag/Ab, and HCV RNA tests. In the
HIV/HCV group, all 100 samples were positive for both anti-HCV and Murex Ag/Ab tests,
whereas 88 patients (88%) were HCV RNA positive. In the uremia group, 14 (69.0%) of the 23
anti-HCV-positive patients were HCV RNA positive, whereas 14 (77.8%) of the 18 Murexry Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou Road,
(J.-F. Huang).
vier Taiwan LLC. All rights reserved.
Murex HCV test for HCV infection 259Ag/Abepositive patients were HCV RNA positive. None of anti-HCV-negative or Murex
Ag/Abenegative patients were HCV RNA positive. Based on the HCV RNA assay, the sensitivities
for both anti-HCV and Murex Ag/Ab assays were 100%, whereas the specificities of these two
assays were 89.7% and 95.4%, respectively. With good sensitivity and specificity, the Murex
Ag/Ab assay could be a useful alternative diagnostic tool, especially in immunocompromised
populations, such as patients with uremia or those infected with HIV.
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.Introduction
With an estimated 170 million infected individuals, hepa-
titis C virus (HCV) infection has an enormous impact on
public health worldwide [1e3]. Therefore, an accurate and
early diagnosis of active HCV infection is critical not only
because of its associated morbidity and mortality but also
because early diagnosis is the most important factor for
a chance of cure, either spontaneously or by antiviral
therapy [4e6].
Commercial assays for anti-HCV antibodies have made
early detection of HCV infection possible since 1990 and
have prevailed since then [7]. With the widespread appli-
cation of the anti-HCV test in the past two decades, more
endemic areas have been discovered and have benefited
from implementation of public health strategies [4,8e11].
Although the anti-HCV test has significantly reduced the
risk of HCV transmission, the window period for detection
of recent or new infection remains a concern. The anti-HCV
antibodies can be detected 7e8 weeks after infection and
usually persist for life. However, false-negative results may
arise in immunocompromised patients, such as those with
human immunodeficiency virus (HIV) infection or uremia. In
the context of HIV infection, the HCV seroconversion delay
is often prolonged [12] and leads to the failure of reactivity
of current anti-HCV antibody detection tests [13]. The
window period can be longer in patients on hemodialysis
(HD) because these individuals are severely immunocom-
promised [14]. In such situations, a highly sensitive and
reliable test is needed for early detection of HCV infection.
Nucleic acid testing (NAT) for HCV RNA was developed as
a more accurate method for disease diagnosis and moni-
toring as well as a confirmatory diagnostic tool for anti-HCV
assays [15e17]. The introduction of NAT has greatly
reduced the risk of HCV transmission [18]. However, its high
cost, liability to environmental contamination, and labo-
rious work have also hampered the wide application of NAT
in clinical settings. Efforts have been made over the past
several years to develop a test that could competently
supplement or eventually replace NAT in the diagnosis of
HCV infection.
The simultaneous detection of both antigen and anti-
body instead of viral nucleic acids was the initial logical
approach. Such detection has been shown to efficiently
shorten the seronegative window for the diagnosis of HIV
infection [19]. A similar approach based on the HCV core
protein and specific anti-HCV antibody detection has
recently been developed for the diagnosis of HCV infection
[20e22].
In this study, we evaluated the clinical performance of
an HCV antigen/antibody combination test (Murex Ag/Abtest; Abbott Laboratories, North Chicago, IL, USA) as
compared with the third-generation HCV antibody enzyme
immunoassay (EIA; AxSYM HCV 3.0, Abbott Laboratories).
Patients with chronic hepatitis C (CHC), patients with dual
HIV/HCV infections, and patients with end-stage renal
disease (ESRD) requiring HD were recruited for the study.
Healthy subjects without HCV or HIV infection served as
controls.
Materials and methods
Patient selection
A total of 403 serum samples were consecutively collected
from four patient groups: healthy controls (nZ 100; 59
men; mean age, 53.4 11.8 years); HCV group (nZ 102;
41 men; mean age, 54.0 10.5 years); HIV/HCV group
(nZ 100; all men; mean age, 36.3 7.5 years); and
uremia group (nZ 101; 46 men; mean age, 59.0 12.9
years). The individuals in the control group were sero-
negative for the anti-HCV test, HCV RNA, HIV, and hepatitis
B surface antigen (HBsAg), and had alanine aminotrans-
ferase (ALT) values within normal limits. The patients in
the HCV group were positive for both the anti-HCV test and
HCV RNA, negative for HIV infection and HBsAg, and had
ALT levels higher than 1.5 times upper normal limit. The
patients in the HIV/HCV group were positive for anti-HIV
and anti-HCV antibodies, whereas the uremic patients
undergoing regular HD were negative for anti-HIV and
HBsAg.
Our research conformed to the Helsinki Declaration. The
present study was approved by the ethics committee of
Kaohsiung Medical University Hospital. All patients gave
informed consent to participate in our study.
Laboratory analyses
The sera were removed from clots within 4 hours of
collection and stored at 70C until needed. ALT levels
were measured on a multichannel autoanalyzer (Architect
ci8200; Abbott Laboratories). HBsAg was detected using
a chemiluminescent microparticle immunoassay (Architect
ci8200; Abbott Laboratories). Anti-HCV antibody was
detected using a third-generation, commercially available
enzyme-linked immunosorbent assay kit (AxSYM HCV 3.0;
Abbott Laboratories) [23]. Serum HCV RNA was detected
using a standardized automated qualitative reverse tran-
scription-polymerase chain reaction assay (COBAS AMPLI-
COR Hepatitis C Virus Test, version 2.0; Roche, Branchburg,
NJ, USA). The detection limit was 50 IU/mL.
Table 1 Comparison of anti-HCV, Murex Ag/Ab, and HCV
RNA assays in uremia and HIV/HCV groups
Uremia group HIV/HCV group
HCV RNA HCV RNA
þ  þ 
Anti-HCV, n (%)
þ 14 (69.0) 9 (39.1) 88 (88.0) 12 (12.0)
 0 78 (100) 0 0
Murex Ag/Ab, n (%)
þ 14 (77.8) 4 (22.2) 88 (88.0) 12 (12.0)
 0 83 (100) 0 0
Anti-HCV: AxSYM HCV 3.0. The third-generation HCV antibody
enzyme immunoassay, S/CO 1Z positive; <1Z negative.
Murex Ag/Ab: Murex HCV Antigen/Antibody Combination Test,
OD for the sample/cutoff OD.
HCV RNA: AMPLICOR HCV Monitor 2.0 assay.
HCVZ hepatitis C virus; HIVZ human immunodeficiency virus;
ODZ optical density; S/COZ sample/cutoff, indicating the OD
of the sample/the OD of the cutoff.
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The Murex Ag/Ab test is a two-step EIA for the detection of
HCV infection [24]. Each sample was tested by a monoclonal
antibody sandwich used for HCV core antigen plus recombi-
nant NS3 protein and core sandwich used for antibody
detection according to the manufacturer’s instructions.
Briefly, 50 mL of sample diluents followed by 50 mL of speci-
mens or controls were added to each of themicroplatewells.
The wells were incubated at 37C for 60 minutes, then
washed five times afterwhich 120 mL of conjugatewas added
to all wells, which were then incubated for 60 minutes at
room temperature (15e28C). The plate was washed five
times and then 80 mL of substrate was added to each of the
wells. The microplate was incubated for 30 minutes at 37C.
Finally, the stop solutionwas added and the plateswere read
at 450/630 nm. A sample was considered positive when its
optical density was greater than or equal to the cutoff value
(determined by the mean of the negative control optical
density divided by 2 plus 0.2).
The overall objective was to determine if this new test
could be an alternative for the diagnosis of HCV infection
during the window period and whether the sensitivity for
antibody detection is preserved. For sera with discrepant
results between the Murex HCV Ag/Ab combination and
AxSYM HCV 3.0, we performed confirmatory tests using the
HCV RNA test.
Statistical analysis
Data were analyzed with Chi-square test or the Fisher’s
exact test, and the Student t test or ManneWhitney test was
used for the baseline characteristics of patients. Differ-
ences were considered significant if the p value was less
than 0.05. In addition, we also evaluated the results of
serum samples from the HIV and uremia patient groups with
AxSYM HCV 3.0, Murex HCV Ag/Ab combination, and HCV
RNA, for sensitivity and specificity. Quality control proce-
dures, database processing, and analyses were performed
using the SPSS 12.0 statistical package (SPSS Inc., Chicago,
IL, USA).
Results
Patients’ characteristics
The mean ALT level in the HCV group was 127.3 175 IU/L,
which was significantly (p< 0.001) higher than the levels in
the HIV/HCV groups (33.7 31.1 IU/L); uremia group
(11.6 14.6 IU/L); and healthy controls (12.8 4.8 IU/L).
In the HCV group, all 102 samples showed concordant
positive results for anti-HCV, Murex Ag/Ab, and HCV RNA
tests. Concordant negative results were also found with
respect to these three assays. In the HIV/HCV group, all 100
samples were positive for both anti-HCV and Murex Ag/Ab
tests, whereas 88 patients (88%) were HCV RNA positive
(Table 1). In the uremia group, 22.8% of patients (23 of 101)
were anti-HCV positive, 17.8% (18 of 101) were Murex
Ag/Ab positive, and 13.9% (14 of 101) were HCV RNA
positive.Comparison of performances among anti-HCV,
Murex Ag/Ab, and HCV RNA assays in the uremia
and HIV/HCV groups
We further analyzed the performance characteristics
among these assays in the uremia group to assess the
inconsistent results. In the uremia group, 14 (69.0%) of the
23 anti-HCV-positive patients were HCV RNA positive,
whereas 14 (77.8%) of the 18 Murex Ag/Abepositive
patients were HCV RNA positive. None of the anti-HCV-
negative or Murex Ag/Abenegative patients was HCV RNA
positive. Taken together, based on HCV RNA assay, the
sensitivities of both anti-HCV and Murex Ag/Ab assays were
100%, whereas the specificities of anti-HCV and Murex Ag/
Ab assays were 89.66% and 95.40%, respectively (Table 1).
The negative predictive values for both anti-HCV and Murex
Ag/Ab assays were 100%, and the positive predictive values
of anti-HCV and Murex Ag/Ab assays were 82.9% and 86.4%,
respectively.
An analysis of the false-positive results by anti-HCV or
Murex Ag/Ab assays in uremia and HIV/HCV patient groups
is shown in Table 2. Five (23.8%) patients (1 man) of the 21
anti-HCV-positive patients were negative for Murex Ag/Ab
assay, and all five patients were HCV RNA negative with
normal ALT levels. Four (25.0%) of the 16 patients positive
for both assays were HCV RNA negative and had normal ALT
levels.
Analysis of negative results by HCV RNA assay
but positive by AxSYM HCV 3.0 assay or Murex
HCV Ag/Ab combination test
In the uremia and HIV groups, 21 samples, 9 in the uremia
group and 12 in the HIV/HCV group, had negative results on
HCV RNA assays with AMPLICOR HCV Monitor 2.0 assay, but
positive results with the AxSYM HCV 3.0 assay or Murex HCV
Ag/Ab combination test. A confirmatory test was performed
in these samples using a recombinant immunoblot assay
Table 2 Analysis of negative results by HCV RNA assay but positive by AxSYM HCV 3.0 assay or Murex HCV Ag/Ab combination
test in uremia and HIV/HCV patient groups
Patient group Sex/age (yr) ALT (IU/L) AxSYM HCV 3.0a Murex HCV Ag/Abb HCV RNAc RIBAd
Uremia M/52 12 þ (55.55) þ (8.166)  
Uremia M/46 8 þ (1.42)  (0.618)  þ
Uremia M/52 8 þ (1.31) þ (2.269)  
Uremia F/74 7 þ (2.18)  (0.558)  
Uremia F/60 11 þ (1.98)  (0.897)  þ
Uremia M/64 8 þ (89.11) þ (3.744)  
Uremia F/51 6 þ (1.34)  (0.797)  
Uremia F/65 4 þ (1.01)  (0.591)  
Uremia F/55 8 þ (6.02) þ (1.472)  
HIV/HCV M/44 14 þ (64.47) þ (8.836)  
HIV/HCV M/29 15 þ (40.57) þ (8.964)  
HIV/HCV M/35 30 þ (45.33) þ (8.243)  
HIV/HCV M/35 6 þ (92.66) þ (9.272)  
HIV/HCV M/50 14 þ (131.81) þ (8.757)  
HIV/HCV M/35 28 þ (33.03) þ (9.131)  
HIV/HCV M/49 20 þ (112.49) þ (7.364)  
HIV/HCV M/40 29 þ (44.01) þ (8.918)  
HIV/HCV M/28 60 þ (38.82) þ (9.403)  
HIV/HCV M/37 12 þ (145.9) þ (9.334)  
HIV/HCV M/46 8 þ (93.32) þ (9.128)  
HIV/HCV M/35 26 þ (78.15) þ (8.033)  
a The third-generation HCV antibody enzyme immunoassay, S/CO 1Z positive; <1Z negative.
b Murex HCV Ag/Ab combination, OD for the sample/cutoff OD.
c AMPLICOR HCV Monitor 2.0 assay.
d Confirmatory tests using RIBA (immunoblot assay).
ALTZ alanine aminotransferase; FZ female; HCVZ hepatitis C virus; HIVZ human immunodeficiency virus; MZmale; ODZ optical
density; RIBAZ recombinant immunoblot assay; S/COZ sample/cutoff, indicating the OD of the sample/the OD of the cutoff.
Murex HCV test for HCV infection 261(RIBA). In the uremia group, all of the results by AxSYM HCV
3.0 assay were discriminative to the HCV RNA assay, and
only two results by the AxSYM HCV 3.0 assay were consis-
tent with the results of RIBA. For the Murex HCV Ag/Ab
combination test, five cases matched with the HCV RNA
assay and three cases matched with RIBA (Table 2). In HIV/
HCV group, all 12 patients with positive results in the AxSYM
HCV 3.0 assay and Murex HCV Ag/Ab combination test
revealed negative results in the HCV RNA assay and RIBA.Discussion
HCV infection is one of the most important causes of liver
cirrhosis and hepatocellular carcinoma with a high impact
on health worldwide [6]. Therefore, early diagnosis of HCV
infection remains a persistent need for identification of the
characteristically asymptomatic viral infection. The
current study covering four different groups of patients in
a clinical setting demonstrated that the Murex Ag/Ab assay
possessed a comparable performance with the anti-HCV
assay in the diagnosis of HCV infection. The concordant
results from the healthy control and HCV groups may
further confirm that it is a useful complementary tool in
screening patients or when NAT is unavailable. Moreover,
the Murex Ag/Ab assay had a higher specificity for detection
in uremic patients, indicating that the Murex Ag/Ab assay is
a competent alternative for detecting HCV infection,
particularly in immunocompromised hosts.Diagnosis of HCV infection largely relies on classical
serologic methods of anti-HCV antibody by EIAs, and it is
confirmed by a positive result obtained using an immunoblot
assay or by the presence of HCVRNA [25]. However, the value
of anti-HCV antibody detection assays is somewhat limited
during the early stages of infection because of the slow
development of specific antibodies. In addition, patients
may fail to develop a strong and rapid specific immune
response against HCV because of their immunocompromised
status. In the window period for diagnosis, the viral load
is very low and despite improvements in the assay for
anti-HCV, the infection goes undetected, more so in immu-
nocompromised patients, such as those with ESRD on main-
tenance HD [26] and patients coinfected with HIV [27,28].
Previous studies have demonstrated that the ratio of HCV
viremia in HCV-seronegative patients on HD was 1e15%
[29,30]. Some studies mentioned that HCV particles may
pass through the dialysis membrane [29] and may even be
destroyed in the process of dialysis; these circumstances
might lead to the low viral load observed in this group of
patients on HD. The reported prevalence of chronic sero-
negative HCV infection among anti-HCV-infected, HIV-
infected patients has varied between 0% and 13.2%
[27,28,31,32]; this variation is possibly the result of immu-
nosuppression, in which case, patients are unable to mount
or maintain HCV antibody titers for detection by standard
serodiagnostic tests [33e35]. The development of new
assays that combine both antigen and antibody detection,
similar to what has been done in the field of HIV detection
262 J.-F. Yang et al.[19], may prove useful in reducing the long window of HCV
seronegativity or in compensating for the absence of
a specific antibody response. This is particularly true in the
immunocompromised patients with HIV coinfection and
ESRD on HD, where long periods of seroconversion have been
described [29,36]. The window period may extend up to
6e12 months in immunocompromised patients [37].
In our analysis, we found no significant difference for
detection of HCV infection between the Murex Ag/Ab and
anti-HCV assays in patients with CHC without an immuno-
compromised status. This implies that these two tests may
be equally reliable in non-immunocompromised patients
with CHC. In the patients in the uremia group in our study,
Murex Ag/Ab and anti-HCV assays had a comparable
performance in terms of sensitivity, when compared with
the HCV RNA assay, and the Murex Ag/Ab assay had better
specificity than the anti-HCV assay. We also found that the
Murex Ag/Ab assay had a higher matching rate with the
HCV RNA assay in discordant results than the anti-HCV
assay in the uremia group. The sensitivity of Murex Ag/Ab
assay was identical with that of the anti-HCV assay in the
HIV group (100%). The Murex Ag/Ab assay may have good
performance in detecting HCV infection, especially in
immunocompromised patients, such as those with uremia
or HIV infection.
Twenty-one serum samples with negative results by the
HCV RNA assay but positive results by the anti-HCV assay or
Murex Ag/Ab assay were found in our study. This result is
consistent with recent data showing that significant
numbers of samples were anti-HCV positive but NAT nega-
tive when tested in a minipool [38]. For example, approx-
imately 30% of anti-HCV-positive donors in Australia had no
detectable HCV RNA [39]. It should be recognized that the
level of viremia declines and fluctuates widely in patients
after seroconversion or during remission [40,41]. Specimens
from these patients may transiently test negative for viral
nucleic acid or viral antigen but may still be infectious
despite the presence of HCV antibodies. In addition, 2 RIBA-
reactive uremic patients were both positive for AxSYM HCV
3.0 but negative for the Murex Ag/Ab assay. These four
assays have different related target regions in the HCV viral
genome: AxSYM HCV 3.0: NS3,NS4; Murex Ag/Ab assay:
core, NS3; HCV RNA assay (COBAS AMPLICOR Hepatitis C
Virus Test, version 2.0): 5’-untranslated region; and RIBA:
NS5, NS3 (c33c, c100p, 5-1-1p, and c22p), which may result
in different reactive patterns in the immunoblot assay. This
may be the reason these two RIBA-reactive uremic patients
were positive on the AxSYM HCV 3.0 but negative on the
Murex Ag/Ab assay. Therefore, NAT will supplement
immunoassays rather than replace them. The HCV Ag/Ab
combination assay was reported to provide earlier detec-
tion of exposure to HCV compared with the anti-HCV anti-
body test; HCV NAT provides even earlier detection than is
afforded by the HCV Ag/Ab combination assay [21,42]. This
newly developed assay was reported to present an
improvement for the detection of HCV infection, especially
in the early phase of infection when antibodies are unde-
tectable. The reductions in the diagnostic window period
observed with the new test and HCV RNA assays were equal,
on average 24 days and 34.4 days, respectively [42].
Because of a cross-sectional design, we could not assess the
data on the reduction in the window period in our analysis.In conclusion, the Murex Ag/Ab assay has good sensitivity
and specificity and could be a useful alternative tool in the
diagnostic setting where procedures to reduce the window
period, such as HCV RNA detection, are not currently rec-
ommended. It could be proposed for use especially in
patients with uremia or those with HIV infection, who have
a high risk of infection and in whom an early diagnosis allows
bettermanagement. This assaymay improve the diagnosis of
HCV infection in addition to the current serologic assays.
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